ALRN
Closed
Aileron Therapeutics Inc
2.05
-0.06 (-2.84%)
Last Update: 07 Feb 2025 17:30:00
Yesterday: 2.11
Day's Range: 2. - 2.295
Send
sign up or login to leave a comment!
When Written:
1.24
Aileron Therapeutics Inc. is a clinical-stage biopharmaceutical company that focuses on developing and commercializing a new class of therapeutics called stapled peptides. These peptides are designed to target intracellular protein-protein interactions, which are implicated in many diseases, including cancer and autoimmune disorders.
The company's lead product candidate, ALRN-6924, is a stapled peptide that targets the p53-MDM2/MDMX interaction, which is a key pathway involved in cancer cell growth and survival. Aileron is developing ALRN-6924 for the treatment of a variety of cancers, including acute myeloid leukemia (AML) and advanced solid tumors.
Aileron was founded in 2005 and is headquartered in Watertown, Massachusetts. The company went public in 2017 and is listed on the NASDAQ stock exchange under the ticker symbol ALRN.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
The company's lead product candidate, ALRN-6924, is a stapled peptide that targets the p53-MDM2/MDMX interaction, which is a key pathway involved in cancer cell growth and survival. Aileron is developing ALRN-6924 for the treatment of a variety of cancers, including acute myeloid leukemia (AML) and advanced solid tumors.
Aileron was founded in 2005 and is headquartered in Watertown, Massachusetts. The company went public in 2017 and is listed on the NASDAQ stock exchange under the ticker symbol ALRN.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!








